News

Keep up with the latest news from the NCI Center for Biomedical Informatics and Information Technology (CBIIT) and the data science communities.

Researchers seeking potential targets for treating childhood cancers now have an even better tool for the job. Check out the latest enhancements to the NCI Childhood Cancer Data Initiative’s (CCDI’s) Molecular Targets Platform.

Funding can be used to support data preparation for inclusion in the National Institute of Allergy and Infectious Diseases (NIAID) Data Ecosystem.

NCI-funded researchers validated a genome-wide artificial intelligence technology that could help in early detection of hepatocellular carcinoma—the most common type of liver cancer.

CCDI additions include molecular characterization data from childhood cancer patients of racial and ethnic diversity.

NCI is soliciting feedback on the utility and future promise of multidimensional tumor atlases for the Human Tumor Atlas Network, including high-priority data types and challenges/opportunities for computational modeling. Your responses are due January 7, 2023.

The latest updates for NCI Enterprise Vocabulary Services include terminology sets for NCI’s Genomic Data Commons, CDISC’s Digital Data Flow project, and a new edition of the NCI Metathesaurus.

Data analysis of the DNA, RNA, protein, and phosphoprotein in lung adenocarcinoma cells connected molecular features of tumors with patient survivability. This study allowed researchers to better predict prognosis and treatment in lung cancer patients.

With help from NCI’s Small Business Innovation Research (SBIR) program, researchers are refining a biophysical simulation technology using computational models for personalized cancer care.

Share your thoughts on how data science can impact cancer’s toughest challenges, and your idea could transform into a team-operated, funded project for resolving that challenge! The deadline is November 28, 2022.

This newly released data set provides imaging in pediatric patients with newly diagnosed primitive neuroectodermal tumors throughout their treatment and until any potential relapse.